{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumor+Cancers", "query": { "condition": "Advanced Solid Tumor Cancers" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 3340, "total_pages": 334, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumor+Cancers&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-21T17:11:58.390Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05397171", "title": "A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Urinary Bladder Neoplasms", "Colorectal Cancer", "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "AZD8853", "type": "DRUG" }, { "name": "Zirconium-89 crefmirlimab berdoxam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 17, "start_date": "2022-06-07", "completion_date": "2023-06-06", "has_results": true, "last_update_posted_date": "2024-10-01", "last_synced_at": "2026-07-21T17:11:58.390Z", "location_count": 4, "location_summary": "Atlanta, Georgia • St Louis, Missouri • Providence, Rhode Island + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05397171" }, { "nct_id": "NCT06384352", "title": "Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "YL211", "type": "DRUG" }, { "name": "YL211+Pembrolizumab", "type": "DRUG" }, { "name": "YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MediLink Therapeutics (Suzhou) Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2024-05-01", "completion_date": "2031-06-30", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-07-21T17:11:58.390Z", "location_count": 11, "location_summary": "Aurora, Colorado • Denver, Colorado • North Haven, Connecticut + 7 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "North Haven", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06384352" }, { "nct_id": "NCT04958434", "title": "Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced or Metastatic Cancers", "Metastatic Human Papillomavirus-Related Malignant Neoplasm" ], "interventions": [ { "name": "TST005", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Suzhou Transcenta Therapeutics Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2021-06-11", "completion_date": "2023-09-30", "has_results": false, "last_update_posted_date": "2023-10-23", "last_synced_at": "2026-07-21T17:11:58.390Z", "location_count": 3, "location_summary": "Canton, Ohio • Dallas, Texas • San Antonio, Texas", "locations": [ { "city": "Canton", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04958434" }, { "nct_id": "NCT05216432", "title": "First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "PIK3CA Mutation", "Solid Tumor, Adult", "HER2-negative Breast Cancer", "Breast Cancer", "Metastatic Breast Cancer", "Advanced Breast Cancer", "Unresectable Solid Tumor" ], "interventions": [ { "name": "RLY-2608", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Palbociclib 125mg", "type": "DRUG" }, { "name": "Ribociclib 400mg", "type": "DRUG" }, { "name": "Ribociclib 600mg", "type": "DRUG" }, { "name": "PF-07220060 100mg", "type": "DRUG" }, { "name": "PF-07220060 300 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Relay Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 930, "start_date": "2021-12-08", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2025-09-22", "last_synced_at": "2026-07-21T17:11:58.390Z", "location_count": 24, "location_summary": "Tucson, Arizona • San Diego, California • Denver, Colorado + 17 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05216432" }, { "nct_id": "NCT06239467", "title": "First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Breast Cancer", "Advanced Solid Tumors", "PI3K Gene Mutation" ], "interventions": [ { "name": "OKI-219", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Tucatinib", "type": "DRUG" }, { "name": "Atirmociclib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OnKure, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2024-02-26", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-07-21T17:11:58.390Z", "location_count": 12, "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 9 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06239467" }, { "nct_id": "NCT02597036", "title": "A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "LY3127804", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2015-11-06", "completion_date": "2020-05-24", "has_results": true, "last_update_posted_date": "2025-10-23", "last_synced_at": "2026-07-21T17:11:58.390Z", "location_count": 2, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02597036" }, { "nct_id": "NCT00729833", "title": "Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Advanced Solid Tumors" ], "interventions": [ { "name": "CP-751,871", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2008-09", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-07-21T17:11:58.390Z", "location_count": 4, "location_summary": "Los Angeles, California • Santa Monica, California • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00729833" }, { "nct_id": "NCT07044336", "title": "Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Cancer", "Malignant Solid Tumour" ], "interventions": [ { "name": "Puxitatug Samrotecan", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 800, "start_date": "2025-08-01", "completion_date": "2029-07-17", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-07-21T17:11:58.390Z", "location_count": 68, "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 59 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07044336" }, { "nct_id": "NCT06105021", "title": "Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Non-Small Cell Lung Cancer", "Colorectal Cancer", "Solid Tumor", "KRAS G12V" ], "interventions": [ { "name": "AFNT-211", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Affini-T Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2024-03-06", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2025-07-30", "last_synced_at": "2026-07-21T17:11:58.390Z", "location_count": 10, "location_summary": "Los Angeles, California • New Haven, Connecticut • New York, New York + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06105021" }, { "nct_id": "NCT07109726", "title": "A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Endometrial Cancer", "Ovarian Cancer", "Lung Squamous Cell Carcinoma", "Head and Neck Squamous Cell Carcinoma", "Esophageal Squamous Cell Carcinoma", "Solid Tumor", "Cervical Cancer" ], "interventions": [ { "name": "TER-2013", "type": "DRUG" }, { "name": "Fulvestrant injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Terremoto Biosciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 205, "start_date": "2025-09-23", "completion_date": "2029-02-28", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-07-21T17:11:58.390Z", "location_count": 14, "location_summary": "Orlando, Florida • Boston, Massachusetts • Rochester, Minnesota + 11 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT07109726" } ] }